CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 24 enrolled
Drug / intervention
rituximabdrug
Likely dose
Not stated in record
Key inclusion· 2
  • ✓Active rheumatoid arthritis
  • ✓Concomitant use of methotrexate
Key exclusion· 2
  • ✕Prior or concurrent use of DMARDs or biologics other than methotrexate
  • ✕Serious medical conditions that would preclude use of the treating agent

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00147966
NCT00147966Phase 2Completed
CompareCT.gov

Assessment of the Immunomodulatory Effects of Rituximab in Seropositive Rheumatoid Arthritis Using Arthroscopic Synovial Biopsies

University of California, San Diego·interventional·Posted Sep 7, 2005·Updated Mar 23, 2010

In Brief

A Phase 2 clinical trial evaluating rituximab for Rheumatoid Arthritis. Completed, enrolled 24 participants across 1 site.

Detailed Summary

Using repeated arthroscopic biopsies of patients with rheumatoid arthritis, the researchers will assess changes in the immune response that occur as a result of treatment with rituximab.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
CountriesUnited States
CollaboratorsGenentech, Inc.

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 7, 2005
Enrollment StartJun 1, 2008
Primary CompletionDec 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 20.8 years ago

Interventions

rituximabdrug

treatment with rituximab